优泌乐25联合拜糖平治疗2型糖尿病疗效观察

The Clinical Effect of Humalog 25 Combined with Acarbose in Type 2 Diabetes Mellitus

目的：探讨优泌乐25联合拜糖平治疗2型糖尿病（T2DM）的临床疗效。方法：将2008年12月-2012年6月我院收治的124例T2DM患者随机分为治疗组和对照组,每组各62例。治疗组采用优泌乐25联合拜糖平治疗,而对照组单用优泌乐治疗,疗程均为12周。观察两组治疗前后血糖水平、血糖达标时间、胰岛素总用量及低血糖发生情况。结果：治疗后,两组FBG、2hBG及HbAlc均较治疗前显著下降（P〈0.05）,而治疗组FBG、2hBG及HbAlc显著低于对照组（P〈0.05）;两组血糖达标时间、胰岛素总用量比较差异有统计学意义（P〈0.05）;治疗组低血糖发生率为4.8%,显著低于对照组19.4%（P〈0.05）。结论：优泌乐25联合拜糖平治疗T2DM安全有效,总体血糖控制较好,低血糖事件发生少,患者的依从性高。

Objective： To explore the efficacy of humalog 25 combined with acarbose in type 2 diabetes mellitus （T2DM）. Methods：124 patients with T2DM who were treated in our hospital from 2008.12 to 2012.6 were randomly divided into two groups：62 cases in treatment group and 64 cases in control group. Treatment group was given humalog 25 combined with acarbose, and control group was given humalog 25 alone. Blood glucose level, the time to reach normal blood glucose level, the total dosage of insulin and the incidence of hypoglycemia were measured in two groups before and after treatment. Results：After treatment, the level of FBG, 2hBG and HbAlc in both groups was significantly decreased （P〈0.05）, but these indicators in treatment group were significantly lower than those in control group （P〈0.05）. There were significantly difference on the time to reach normal blood glucose level and the total dosage of insulin between the two groups （P〈0.05）. The incidence of hypoglycemic between the two groups （4.8%vs. 19.4%） were significantly different （P〈0.05）. Conclusion：It is effective and safe of humalog 25 combined with acarbose in treating T2DM, and it has the advantage of better blood glucose control, less hypoglycemic events, and high patients’ compliance.